

Antifungal Activity of *Tithonia diversifolia* Leaf Ethanol Extract Against *Candida albicans*: A Dose-Response Study

Tantri Dyah Whidi Palupi^{1*} 

¹Division of Veterinary Anatomy, Faculty of Veterinary Medicine, Universitas Airlangga, Jl. Dr. Ir. H. Soekarno, Kampus C Mulyorejo, Surabaya 60115, East Java, Indonesia

ARTICLE INFO

ABSTRACT

This study aimed to evaluate the antifungal activity of *Tithonia diversifolia* (Hemsl.) A. Gray leaf ethanol extract against *Candida albicans*, focusing on identifying both the minimum inhibitory and maximum effective concentrations. Twelve treatments were applied using the paper disk diffusion method, including extract concentrations ranging from 10% to 100%, a positive control (ketoconazole), and a negative control (1% DMSO). Inhibition zone diameters were measured and statistically analyzed using one-way ANOVA followed by Duncan's multiple range test. The extract exhibited antifungal activity at a 50% concentration, with the strongest inhibition observed at 90%. These findings indicate the potential of *T. diversifolia* as a natural antifungal agent and support the exploration of plant-based alternatives to conventional antifungal drugs. This approach contributes to improving public health through the development of accessible, affordable treatments and highlights the importance of conserving biodiversity by utilizing locally available medicinal plants in biomedical research.

Keywords: *Tithonia diversifolia*, *Candida albicans*, antifungal, ethanol extract, medicinal plants

Original Research

Received: April 21, 2025

Accepted: May 29, 2025

Published: June 28, 2025

***Corresponding Author:**

dyah.whidi@fkh.unair.ac.id

DOI:

<https://doi.org/agroveter.v8i2.74110>

Introduction

Candidiasis, a disease caused by an overgrowth of the *Candida species*, particularly *Candida albicans*, can lead to illnesses in both animals and humans, causing immune suppression or debilitating diseases, with the predisposing factors to this overgrowth including young birds that are not fully immunocompetent, prolonged antibiotic use, concurrent immunosuppressive conditions (e.g., debilitation, PBFD, malnutrition), poor hygiene in the bird's environment and food preparation, failure to clean excess formula from the skin or mouth of hand-reared chicks, high concentrations of sugar in fruit and hand-rearing formula providing an optimal medium for the growth of yeast, and alkaline crop contents, observed when crop stasis occurs for any reason, enhancing yeast overgrowth (Al-Abedi, et al., 2024; Talazadeh, et al., 2022). This fungal infection has been reported in both domestic and

wild birds, with confirmed cases in Galliformes (chickens, turkeys, quail), Anseriformes (ducks, geese), Psittaciformes (parrots), Passeriformes (songbirds), Columbiformes (pigeons), and Guinea fowl (Talazadeh, et al., 2022), candida infection also leading to decreased growth rates, poor feed conversion, and increased mortality, all of which contribute to economic losses. The cost of treatment and preventive measures further adds to the financial burden (Dias Carneiro, et al., 2024; Domán, et al., 2023; Talazadeh, et al., 2022).

Azole compounds, including ketoconazole, are the primary antifungal agents used to treat candidiasis. These compounds function by targeting the fungal cell membrane, specifically by inhibiting the enzyme lanosterol 14 α -demethylase, which is crucial for ergosterol synthesis, a key component of the fungal cell membrane (Suat, et al., 2020; Bruneau, et al.,

2003). While ketoconazole is effective against various pathogenic yeasts, The efficacy of azoles is often compromised by the development of resistance in *Candida* species. Resistance mechanisms include overexpression of efflux pumps and mutations in the target enzyme CYP51 (Nishimoto, et al., 2020).

Due to concerns regarding drug safety, resistance, and accessibility, attention has turned to medicinal plants as alternative antifungal agents. *Tithonia diversifolia* (Hemsl.) A. Gray, commonly known as tree marigold, has garnered attention for its potential as an alternative antifungal agent due to its rich composition of bioactive phytochemicals such as flavonoids, tannins, alkaloids, and saponins, contributing to its antimicrobial properties especially the phenolic compounds and flavonoids (Barboza, et al., 2018). Flavonoids are known to exert antifungal effects through multiple mechanisms. Compounds such as sophoraflavone G and (-)-epigallocatechin gallate have been shown to disrupt cytoplasmic membrane function, leading to fungal cell death. In addition, flavonoids inhibit key enzymes like DNA gyrase, interfere with the energy metabolism of yeasts and fungi, and block ATP-dependent drug efflux pumps, which are often responsible for antifungal resistance. Microscopic analyses using SEM and TEM have further demonstrated that flavonoid derivatives induce abnormal hyphal growth, distorted cell walls, and a reduction in mitochondrial numbers in fungi such as *Rhizoctonia solani* (Peng, et al., 2024; Cushnie and Lamb, 2005)

Given its phytochemical profile and prior indications of antifungal activity, this study aimed to evaluate the inhibitory effect of ethanol extracts from *T. diversifolia* leaves against *Candida albicans*. The specific objectives were to determine the minimum concentration required to inhibit fungal growth and to identify the concentration with the maximum inhibitory effect.

Materials and methods

Research design

This study utilized a true experimental

design with a post-test control group format to investigate the antifungal effects of ethanol extract derived from *Tithonia diversifolia* (Hemsl.) A. Gray leaves against *Candida albicans*, employing the disk diffusion technique.

Sample and test organism

The test organism used was *Candida albicans* ATCC 10231, obtained from Balai Besar Laboratorium Kesehatan (BBLK), Surabaya, Indonesia. The suspension was prepared to match the turbidity of 0.5 McFarland standard (equivalent to 1.5×10^8 CFU/mL).

Preparation of plant extract

Fresh *Tithonia diversifolia* (Hemsl.) A. Gray leaves were cleaned, air-dried, and finely ground into powder form. The extraction process involved maceration in 96% ethanol for 72 hours with occasional stirring. The resulting solution was then concentrated using a rotary evaporator at a temperature range of 50–60°C to produce a viscous ethanol extract. This extract was subsequently diluted in 1% dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany; Cat. No. 102952) to prepare a series of concentrations: 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%.

Antifungal assay

The antifungal effect was evaluated using the paper disk diffusion technique on Sabouraud Dextrose Agar (SDA; Merck, Darmstadt, Germany; Cat. No. 105438) plates containing chloramphenicol. Plates were inoculated with a suspension of *Candida albicans* and treated with sterile paper disks loaded with 20 µL of each extract concentration. Ketoconazole (0.125 µg/disc) served as the positive control, while 1% dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany; Cat. No. 102952) was used as the negative control. All assays were conducted in triplicate.

Incubation and observation

The inoculated plates were incubated at 37°C for 24 hours. Antifungal activity was determined by measuring the diameter of the

clear zones of inhibition around the paper disks in millimeters. Each zone was measured in three different directions, and the average value was calculated.

Data analysis

The data were subjected to one-way ANOVA analysis, followed by Duncan's multiple range test to identify statistically significant differences between treatment groups, with a significance level set at $p < 0.05$.

Result

The antifungal potential of ethanol leaf extracts from *Tithonia diversifolia* (Hemsl.) A. Gray against *Candida albicans* was investigated through the measurement of inhibition zones on Sabouraud Dextrose Agar (SDA) using the disk diffusion method. This experiment involved twelve treatment groups, comprising ten extract concentrations ranging from 10% to 100%, as well as a positive control (ketoconazole 0.125 µg/disc) and a negative control (1% dimethyl sulfoxide, DMSO).

The data revealed that lower extract concentrations of 10% and 20% exhibited no visible inhibition zones, with average diameters of 6.00 ± 0.00 mm, identical to the negative control, indicating a lack of antifungal activity at these levels. Beginning at a concentration of 30%, a slight antifungal effect was observed (6.22 ± 0.39 mm), which gradually increased with higher extract concentrations. Notably, extracts at 90% and 100% produced the largest inhibition zones among all extract groups, measuring 15.44 ± 2.88 mm and 16.67 ± 2.22 mm, respectively. Despite this, both values remained lower than the inhibition diameter produced by the positive control ketoconazole, which showed a consistent zone of 20.00 ± 0.00 mm.

Furthermore, the negative control (1% DMSO) showed no inhibitory activity, confirming that the solvent alone did not contribute to fungal growth suppression. Statistical analysis using one-way ANOVA followed by Duncan's multiple range test demonstrated significant differences ($p < 0.05$)

among most treatments, particularly when comparing extract concentrations of 50% and above to the negative control. The analysis indicated that 50% was the minimum effective concentration that produced a statistically significant antifungal effect. The antifungal efficacy continued to improve with increasing concentration up to 90%, beyond which the effect plateaued.

A summary of the inhibition zone diameters observed across all treatments is presented in Table 1.

Table 1. The summary of the average inhibition zone diameters observed in each treatment.

Treatments	Mean Inhibition Zone (mm) ± SD
P (+)	20.00 ± 0.00^e
P (-)	6.00 ± 0.00^a
P1	6.00 ± 0.00^a
P2	6.00 ± 0.00^a
P3	6.22 ± 0.39^a
P4	7.43 ± 0.21^{ab}
P5	8.55 ± 0.69^{bc}
P6	9.00 ± 0.58^{bc}
P7	10.56 ± 1.90^c
P8	10.76 ± 1.71^c
P9	15.44 ± 2.88^d
P10	16.67 ± 2.22^d

Note: Distinct superscript letters denote statistically significant differences among groups at the 5% significance level.

These findings indicate a dose-dependent relationship between the concentration of *Tithonia diversifolia* (Hemsl.) A. Gray ethanol leaf extract and its antifungal activity against *Candida albicans*. The results support the conclusion that the extract begins to exert significant inhibitory effects starting from 50% concentration, with optimal performance observed at 90%.

Discussion

The present study demonstrates that the ethanol extract derived from the leaves of *Tithonia diversifolia* (Hemsl.) A. Gray possesses

antifungal properties against *Candida albicans*, showing a clear dose-dependent pattern. While concentrations below 30% did not exhibit observable inhibitory effects, a measurable inhibition zone was detected at 30%, becoming more pronounced at 50% and reaching its maximum at 90%. Nonetheless, the antifungal activity of the extract remained consistently less effective than that of ketoconazole.

Candida albicans is a commensal yeast frequently found on mucosal surfaces in humans and animals, which may transition to a pathogenic state when host immunity is impaired or the normal microbiota is disrupted. In veterinary medicine, candidiasis has been associated with considerable mortality and economic losses, particularly among avian populations (Benarrós & Salvarani, 2024; Jacobsen *et al.*, 2021; Basmaciyan *et al.*, 2019).

Ketoconazole, used as the positive control in this study, exerts its antifungal action by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. This disruption compromises fungal cell integrity and viability (Lisa *et al.*, 2022). However, despite its efficacy, ketoconazole is linked to several adverse effects, including liver toxicity, reproductive toxicity in males, and teratogenic outcomes (Adis Medical Writer, 2020). Furthermore, the emergence of antifungal-resistant *Candida* species such as *C. auris*, *C. glabrata*, and *C. tropicalis* has intensified the challenges in managing fungal infections (Raposa & Vazquez, 2025; Murphy & Bicanic, 2021). Resistance mechanisms may involve modifications in drug target enzymes, overexpression of efflux pumps, and biofilm formation, all of which hinder treatment success and highlight the urgency of developing alternative antifungal agents (Chauhan *et al.*, 2025; Shivarathri *et al.*, 2020). The rising incidence of azole resistance, including resistance to ketoconazole, further emphasizes the importance of identifying novel antifungal candidates (Jangir *et al.*, 2023).

Plant-derived antifungal agents have gained attention due to their potential efficacy and lower toxicity profiles. Bioactive

compounds such as terpenoids, phenolics, and essential oils have exhibited antifungal effects against a variety of *Candida* species (Sharma *et al.*, 2025). The antifungal activity observed in *Tithonia diversifolia* is likely attributable to its diverse phytochemical constituents, including flavonoids, tannins, alkaloids, saponins, and phenolic compounds (Babii *et al.*, 2021; Barboza *et al.*, 2018). Specifically, flavonoids have been shown to impair fungal cell membranes, inhibit efflux pump activity, disrupt cell wall integrity, and induce programmed cell death (Rodriguez *et al.*, 2023; Babii *et al.*, 2021; Barboza *et al.*, 2018). These mechanisms are likely responsible for the inhibition observed in *C. albicans*.

The positive association between extract concentration and antifungal activity corroborates findings from prior research (Marbun *et al.*, 2022), emphasizing the critical role of compound concentration in determining antimicrobial effectiveness. Although the extract did not exceed the efficacy of ketoconazole, its notable inhibitory effect at higher concentrations indicates promising potential as a natural antifungal agent.

Future investigations should aim to isolate and characterize the bioactive constituents responsible for the antifungal effect of *Tithonia diversifolia*, followed by in vivo evaluation. Such studies are essential to support the development of accessible and low-toxicity antifungal therapies, especially in the context of increasing resistance to conventional drugs.

Conclusion

The ethanol extract of *Tithonia diversifolia* (Hemsl.) A. Gray leaves demonstrated dose-dependent antifungal activity against *Candida albicans*. Observable inhibition began at 30%, with significant effects at 50%, and maximum activity at 90% concentration. Although its efficacy was lower than ketoconazole, the extract's antifungal potential suggests it contains bioactive compounds worthy of further investigation. Future research should aim to isolate these compounds and assess their effectiveness in vivo to support the development of safe, natural antifungal therapies.

References

- Adis Medical Writers. Long-term use of systemic azole antifungals can result in hepatotoxicity and other serious adverse effects. *Drugs Ther Perspect.* 2020; 36: 112–115.
- Al-Abedi H, Khalil I, Al-Abedi S. Molecular detection of Virulence Factor Genes in *Candida albicans* Isolated from the Oral Cavity of Local Chicken and Antifungal Susceptibility in Mosul Province. *Al-Kitab Journal for Pure Sciences.* 2024; 8(2):1-10.
- Babii C, Savu M, Motrescu I, Birsa LM, Sarbu LG, Stefan M. The Antibacterial Synthetic Flavonoid BrCl-Flav Exhibits Important Anti-*Candida* Activity by Damaging Cell Membrane Integrity. *Pharmaceuticals,* 2021; 14(11): 1130.
- Basmaciyan L, Bon F, Paradis T, Lapaquette P, Dalle F. *Candida albicans* interactions with the host: Crossing the intestinal epithelial barrier. *Tissue Barriers.* 2019; 7(2): 1612661
- Barboza BR, da Silva Barros BR, Ramos BDA, de Moura MC, Napoleão TH, dos Santos Correia MT, Barroso Coelho LC, da Cruz Filho IJ, Souto Maior AM, da Silva TD, Rodrigues Nerys LDC, de Santana ERB, de Andrade Lima CS, de Lorena VMB, de Melo CML. Phytochemical bioprospecting, antioxidant, antimicrobial and cytotoxicity activities of saline extract from *Tithonia diversifolia* (Hemsl) A. Gray leaves. *Asian Pacific Journal of Tropical Biomedicine.* 2018; 8(5):245-253.
- Benarrós MSC, Salvarani FM. Candidiasis in *Choloepus* sp.—A Review of New Advances on the Disease. *Animals.* 2024; 14(14): 2092.
- Bruneau JM, Maillet I, Tagat E, Legrand R, Supatto F, Fudali C, Caer JP, Labas V, Lecaque D, Hodgson J. Drug induced proteome changes in *Candida albicans*: Comparison of the effect of β (1,3) glucan synthase inhibitors and two triazoles, fluconazole and itraconazole. *Proteomics.* 2003; 3(3): 325–336.
- Chauhan M, Shivarathri R, Aptekmann AA, Chowdhary A, Kuchler K, Desai JV, Chauhan N. The Gcn5 lysine acetyltransferase mediates cell wall remodeling, antifungal drug resistance, and virulence of *Candida auris*. *mSphere.* 2025; 10:e00069-25.
- Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids. *International Journal of Antimicrobial Agents.* 2005; 26(5):343-356.
- Domán M, Makrai L, Vászrhelyi B, Balka G, Bányai K. Molecular epidemiology of *Candida albicans* infections revealed dominant genotypes in waterfowls diagnosed with esophageal mycosis. *Frontiers in Veterinary Science.* 2023; 10(2023):1215624.
- Dias Carneiro H, Dias T, Fialho DS, Rocha E, Dias M, Costa CH, Pereira V, Abreu D. Candidosis in Guinea Fowl (*Numida meleagris*). *Acta Scientiae Veterinariae.* 2024; 52(2024).
- Jacobsen ID, Niemiec MJ, Kapitan M, Polke M. Commensal to Pathogen Transition of *Candida albicans*. *Encyclopedia of Mycology.* 2021; 507-525.
- Jangir P, Kalra S, Tanwar S, Bari VK. Azole resistance in *Candida auris*: mechanisms and combinatorial therapy. *Journal of Pathology, Microbiology and Immunology.* 2023; 131(8):442-462.
- Lisa EL, Dragostin OM, Petroaie AD, Gurau G, Cristea A, Pavel A, Bonifate F, Popa PS, Matei M. The Effect of the New Imidazole Derivatives Complexation with Betacyclodextrin, on the Antifungal Activity in Oropharyngeal Infections. *Processes.* 2022; 10(12): 2697.
- Marbun N, Simanjuntak Y, Manalu R, Ramadhan M. Uji Aktivitas Antifungi Ekstrak Etanol Herba Kembang Bulan (*Tithonia diversifolia* (Hemsl.)Gray) Terhadap *Candida albicans* dan *Microsporum canis*. *Herbal Medicine*

- Journal*. 2022; 5(1):24-27.
- Murphy SE, Bicanic T. Drug resistance and novel therapeutic approaches in invasive candidiasis. *Frontiers in Cellular and Infection Microbiology*. 2021; 11:759408.
- Nishimoto AT, Sharma C, Rogers PD. Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus *Candida albicans*. *Journal of Antimicrobial Chemotherapy*. 2020; 75(2): 257–270.
- Peng D, Yufei L, Zihua M, Jian J, Qing X, Weihua Z. Design, Synthesis, Antifungal Evaluation, and Three-Dimensional Quantitative Structure–Activity Relationship of Novel 5-Sulfonyl-1,3,4-thiadiazole Flavonoids. *Journal of Agricultural and Food Chemistry*. 2024; 72(39): 21419-21428.
- Raposa J, Vazquez A. New pharmacotherapeutic strategies for drug-resistant *Candida* infections: a review. *Expert Opinion on Pharmacotherapy*. 2025; 1–11.
- Rodríguez IS, Valdés LS, Vázquez TER. Phytochemical composition of *Tithonia diversifolia* (Hemsl.) materials collected in eastern Cuba. *Revista Cubana de Plantas Medicinales*. 2023; 28(4):e1488.
- Sharma D, Gautam S, Singh S, Srivastava N, Khan AM and Bisht D. Unveiling the nanoworld of antimicrobial resistance: integrating nature and nanotechnology. *Frontiers in Microbiology*. 2025; 15:1391345.
- Shivarathri R, Jenull S, Stoiber A, Chauhan M, Mazumdar R, Singh A, Nogueira FKuchler K, Chowdhary A, Chauhan N. The Two-Component Response Regulator Ssk1 and the Mitogen-Activated Protein Kinase Hog1 Control Antifungal Drug Resistance and Cell Wall Architecture of *Candida auris*. *mSphere*. 2020; 5:10.1128/msphere.00973-20.
- Suat S, Ahmet, Ebru K, Didem, Suna S, İnci SD, Zeynep Ö, İrem B, Arzu K, Selma S, Sevim D. Antibacterial azole derivatives: Antibacterial activity, cytotoxicity, and in silico mechanistic studies. *Drug Development Research*. 2020; 81(8): 1026-1036.
- Talazadeh F, Ghorbanpoor M, Shahriyari A. Candidiasis in Birds (Galliformes, Anseriformes, Psittaciformes, Passeriformes, and Columbiformes): A Focus on Antifungal Susceptibility Pattern of *Candida albicans* and Non-*albicans* Isolates in Avian Clinical Specimens. *Topics in companion animal medicine*. 2022; 46:100598.